How I Treat ALL: What Are the Best Treatments for Relapsed ALL?
Anjali Advani, MD, Cleveland Clinic
Friday, September 8, 2017 4:30 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL
The prognosis of adult patients with acute lymphocytic leukemia (ALL) in first relapse is poor (less than 10 percent overall survival at five years), and better approaches are clearly needed. This session will review the novel agents that are either FDA approved (e.g., blinatumomab) or in clinical trials (e.g., CAR T cells and inotuzumab) in the treatment of relapsed disease.
About the Speaker
Anjali Advani, MD, is Director of the Inpatient Leukemia Program and a Staff Physician in the Department of Hematology/Oncology at the Cleveland Clinic. She is Associate Professor in the Cleveland Clinic Lerner College of Medicine and Chair of the Data Safety and Monitoring Board for Case Comprehensive Cancer Center. Dr. Advani’s research has focused on novel therapies for acute lymphocytic and acute myeloid leukemia. She is a member of the SWOG Leukemia Committee, where she is the national principal investigator for several clinical trials in acute leukemia.
back to top